Literature DB >> 22956232

α-Synuclein oligomers: an amyloid pore? Insights into mechanisms of α-synuclein oligomer-lipid interactions.

Martin T Stöckl1, Niels Zijlstra, Vinod Subramaniam.   

Abstract

In many human diseases, oligomeric species of amyloid proteins may play a pivotal role in cytotoxicity. Many lines of evidence indicate that permeabilization of cellular membranes by amyloid oligomers may be the key factor in disrupting cellular homeostasis. However, the exact mechanisms by which the membrane integrity is impaired remain elusive. One prevailing hypothesis, the so-called amyloid pore hypothesis, assumes that annular oligomeric species embed into lipid bilayers forming transbilayer protein channels. Alternatively, an increased membrane permeability could be caused by thinning of the hydrophobic core of the lipid bilayer due to the incorporation of the oligomers between the tightly packed lipids, which would facilitate the transport of small molecules across the membrane. In this review, we briefly recapitulate our findings on the structure of α-synuclein oligomers and the factors influencing their interaction with lipid bilayers. Our results, combined with work from other groups, suggest that α-synuclein oligomers do not necessarily form pore-like structures. The emerging consensus is that local structural rearrangements of the protein lead to insertion of specific regions into the hydrophobic core of the lipid bilayer, thereby disrupting the lipid packing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956232     DOI: 10.1007/s12035-012-8331-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  60 in total

1.  Structural properties of pore-forming oligomers of alpha-synuclein.

Authors:  Hai-Young Kim; Min-Kyu Cho; Ashutosh Kumar; Elke Maier; Carsten Siebenhaar; Stefan Becker; Claudio O Fernandez; Hilal A Lashuel; Roland Benz; Adam Lange; Markus Zweckstetter
Journal:  J Am Chem Soc       Date:  2009-12-02       Impact factor: 15.419

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein.

Authors:  Joanna Kaylor; Nika Bodner; Shauna Edridge; Ghiam Yamin; Dong-Pyo Hong; Anthony L Fink
Journal:  J Mol Biol       Date:  2005-10-21       Impact factor: 5.469

4.  Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.

Authors:  A E Roher; M O Chaney; Y M Kuo; S D Webster; W B Stine; L J Haverkamp; A S Woods; R J Cotter; J M Tuohy; G A Krafft; B S Bonnell; M R Emmerling
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

5.  Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form.

Authors:  He-Jin Lee; Chan Choi; Seung-Jae Lee
Journal:  J Biol Chem       Date:  2001-10-25       Impact factor: 5.157

6.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

Review 7.  Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Authors:  Michael J Volles; Peter T Lansbury
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

8.  Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing.

Authors:  Bart D van Rooijen; Mireille M A E Claessens; Vinod Subramaniam
Journal:  FEBS Lett       Date:  2008-10-16       Impact factor: 4.124

9.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Authors:  Hilal A Lashuel; Benjamin M Petre; Joseph Wall; Martha Simon; Richard J Nowak; Thomas Walz; Peter T Lansbury
Journal:  J Mol Biol       Date:  2002-10-04       Impact factor: 5.469

10.  Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers.

Authors:  Marcus Kostka; Tobias Högen; Karin M Danzer; Johannes Levin; Matthias Habeck; Andreas Wirth; Richard Wagner; Charles G Glabe; Sabine Finger; Udo Heinzelmann; Patrick Garidel; Wenzhen Duan; Christopher A Ross; Hans Kretzschmar; Armin Giese
Journal:  J Biol Chem       Date:  2008-02-07       Impact factor: 5.157

View more
  29 in total

1.  Assembly of α-synuclein aggregates on phospholipid bilayers.

Authors:  Zhengjian Lv; Mohtadin Hashemi; Siddhartha Banerjee; Karen Zagorski; Jean-Christophe Rochet; Yuri L Lyubchenko
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2019-06-19       Impact factor: 3.036

Review 2.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

3.  Toxic HypF-N Oligomers Selectively Bind the Plasma Membrane to Impair Cell Adhesion Capability.

Authors:  Reinier Oropesa-Nuñez; Sandeep Keshavan; Silvia Dante; Alberto Diaspro; Benedetta Mannini; Claudia Capitini; Cristina Cecchi; Massimo Stefani; Fabrizio Chiti; Claudio Canale
Journal:  Biophys J       Date:  2018-03-27       Impact factor: 4.033

4.  How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro.

Authors:  Nikolai Lorenzen; Søren B Nielsen; Yuichi Yoshimura; Brian S Vad; Camilla Bertel Andersen; Cristine Betzer; Jørn D Kaspersen; Gunna Christiansen; Jan S Pedersen; Poul Henning Jensen; Frans A A Mulder; Daniel E Otzen
Journal:  J Biol Chem       Date:  2014-06-06       Impact factor: 5.157

5.  Real-time determination of aggregated alpha-synuclein induced membrane disruption at neuroblastoma cells using scanning ion conductance microscopy.

Authors:  Stephanie Wong Su; Andy Chieng; Jacob Parres-Gold; Megan Chang; Yixian Wang
Journal:  Faraday Discuss       Date:  2018-10-01       Impact factor: 4.008

6.  Heme Stabilization of α-Synuclein Oligomers during Amyloid Fibril Formation.

Authors:  Eric Y Hayden; Prerna Kaur; Thomas L Williams; Hiroshi Matsui; Syun-Ru Yeh; Denis L Rousseau
Journal:  Biochemistry       Date:  2015-07-24       Impact factor: 3.162

7.  Structures and dynamics of β-barrel oligomer intermediates of amyloid-beta16-22 aggregation.

Authors:  Xinwei Ge; Yunxiang Sun; Feng Ding
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-03-14       Impact factor: 3.747

8.  Cortical phosphorylated α-Synuclein levels correlate with brain wave spectra in Parkinson's disease.

Authors:  John N Caviness; Lih-Fen Lue; Joseph G Hentz; Christopher T Schmitz; Charles H Adler; Holly A Shill; Marwan N Sabbagh; Thomas G Beach; Douglas G Walker
Journal:  Mov Disord       Date:  2016-04-08       Impact factor: 10.338

9.  A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.

Authors:  Wolfgang Wrasidlo; Igor F Tsigelny; Diana L Price; Garima Dutta; Edward Rockenstein; Thomas C Schwarz; Karin Ledolter; Douglas Bonhaus; Amy Paulino; Simona Eleuteri; Åge A Skjevik; Valentina L Kouznetsova; Brian Spencer; Paula Desplats; Tania Gonzalez-Ruelas; Margarita Trejo-Morales; Cassia R Overk; Stefan Winter; Chunni Zhu; Marie-Francoise Chesselet; Dieter Meier; Herbert Moessler; Robert Konrat; Eliezer Masliah
Journal:  Brain       Date:  2016-09-27       Impact factor: 13.501

10.  Formation and propagation of tau oligomeric seeds.

Authors:  Julia E Gerson; Rakez Kayed
Journal:  Front Neurol       Date:  2013-07-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.